France’s Highest Health Authority Recommends a Selective Ban of Hydroxychloroquine

France’s highest health authority, the “Haut Conseil de la Santé Publique” issued new restrictive recommendations for hydroxychloroquine.

It was France’s Health Minister Olivier Véran who, last Saturday, had requested recommendations within 48 hours.

Minister Véran’s request was founded on the findings of The Lancet study published the day before, that claims that hydroxychloroquine is ineffective and unsafe.

The Lancent study rapidly came under the scrutiny of numerous observers around the world. It now increasingly looks like a fraud, relying on cooked data, with numerous conflicts of interests among the study authors.

The questionability of the study did not stop France’s highest authority to make extremely stringent recommendations.

“Hydroxychloroquine, alone or associated with a macrolide, should not be used for the treatment of COVID-19”

It further states that a risk / benefit analysis about the use of hydroxychloroquine should be evaluated in the context of clinical trials.

A third recommendation is that national and international regulations should be reinforced regarding the use of hydroxychloroquine in the context of clinical trials.

France highest health authority states that “standard care” (i.e. no treatment) should remain the treatment of reference for COVID-19

Yesterday, Professor Raoult publicly criticized The Lancet study, as we reported.

Professor Raoult further blasted The Lancet study this morning through Twitter.

The article below is one of many analysis available online showing major flaws in The Lancet study.

Note that the authors are refusing to make public the data of the study. At the same time, It’s unclear how it could have been possible to collect this data without infringing multiple privacy laws.

We will publish shortly a video interview, in French, of sociologist Laurent Mucchielli, PHD, who also carried out a detailed analysis of The Lancet study and concludes to a possible fraud.

See this just published article by Laurent Mucchiellli about the affair.

How will the Macron government react to this recommendation remains to be seen.

It’s usually commented that France’s Health Minister is pursuing a form of personal vendetta against Professor Raoult.

Will minister Véran be followed in this endeavour by President Macron and the French government?

It’s indeed becoming clear that there is a major manipulation under way, and that the new restrictions on hydroxychloroquine were not decided on the basis of science but rather on a possible fraud.

Is the French government a victim of what increasingly appears to be a major manipulation, or is it part of it?

In France, there are already major restrictions on the use of hydroxychloroquine, and numerous medical doctors, especially general practitioners, have demanded, with no effect, to be authorized to prescribe the medication.

Could France decide to prevent hydroxychloroquine prescriptions even in hospitals, where it is presently allowed?

Remember, it’s one hospital in France, Professor Raoult’s IHU-Marseille, that has achieved the best results world-wide in treating COVID-19, with a minimal case fatality of 0.5%.

Most countries have much higher fatality rates, of 5%, 10% or more. Such higher fatality rates can also be found in most France’s regions – especially Paris, which was highly impacted by the pandemic.

Note that the World Health Organization has also decided to stop the use of hydroxychloroquine in the context of its SOLIDARITY research program, following The Lancet article.

While there is ample evidence now that there are effective treatments for COVID-19, the official position of the World Health Organization is still that such effective treatments don’t exist.


Covid-19 : utilisation de l’hydroxychloroquine

Le HCSP a ré examiné le positionnement de l’hydroxychloroquine dans la prise en charge du Covid-19. Le groupe de travail multidisciplinaire a analysé les recommandations internationales relatives à la prescription de l’hydroxychloroquine dans le Covid-19, les publications sur le sujet, dont l’article du Lancet, les rapports des centres régionaux de pharmacovigilance rapportant des effets secondaires potentiellement graves, en particulier cardiovasculaires, en lien avec l’utilisation de ce médicament. Le groupe de travail a conclu de manière collégiale à l’absence d’étude clinique suffisamment robuste démontrant l’efficacité de l’hydroxychloroquine dans le Covid-19 quelle que soit la gravité de l’infection.
Le HCSP recommande :

  • De ne pas utiliser l’hydroxychloroquine (seule ou associée à un macrolide) dans le traitement du Covid-19
  • D’évaluer le bénéfice/risque de l’utilisation de l’hydroxychloroquine dans les essais thérapeutiques
  • De renforcer la régulation nationale et internationale des différents essais évaluant l’hydroxychloroquine dans le Covid-19.
    A ce stade des connaissances, le traitement dit « standard of care » demeure le traitement de référence.